<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05797259</url>
  </required_header>
  <id_info>
    <org_study_id>DANCN 01</org_study_id>
    <nct_id>NCT05797259</nct_id>
  </id_info>
  <brief_title>RANKL Antibody for Acute Charcot Neuro-osteoarthropathy</brief_title>
  <acronym>DANCN-CKD</acronym>
  <official_title>RANKL Antibody (Danosumab) for Acute Charcot Neuro-osteoarthropathy Remission in Chronic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Postgraduate Institute of Medical Education and Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Postgraduate Institute of Medical Education and Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study's goal was to determine how denosumab 60 mg, combined with total contact casting&#xD;
      and restricted weightbearing status, would affect the treatment of acute CN with CKD.&#xD;
&#xD;
      METHODS Participants in the research were those who visited the outpatient foot clinic at&#xD;
      PGIMER, CHD in India. During the study period, 446 persons with CN were identified, 102 of&#xD;
      whom met the criteria for the first screening, and 60 of whom were ultimately enrolled in the&#xD;
      study.&#xD;
&#xD;
      Aim: To assess the clinico-radiological remission of Acute Charcot-neuroarthropathy in&#xD;
      patients of CKD.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 10, 2019</start_date>
  <completion_date type="Anticipated">March 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Remission of acute charcot</measure>
    <time_frame>30 months</time_frame>
    <description>Proportion of patients achieving remission</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Remission duration</measure>
    <time_frame>30 months</time_frame>
    <description>Remission duration in weeks or months</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">78</enrollment>
  <condition>Charcot Joint of Foot</condition>
  <arm_group>
    <arm_group_label>Danosumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Danosumab 60mg subcutaneous once at diagnosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal Saline equal volume subcutaneous once at diagnosis</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Danosumab</intervention_name>
    <description>60 mg subcutaneous Danosumab</description>
    <arm_group_label>Danosumab</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Drug Arm</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Diabetes Active Charcot neuroarthropathy of foot Chronic Kidney disease defined as eGFR&lt;60&#xD;
        ml/min/m2 and/or Urine protein &gt;300 mg/day Presence of all&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Active Pedal ulcer Active malignancy Hypocalcemia Primary Hyperparathyroidism Pregnancy and&#xD;
        Breast Feeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Deptt of Endocrinology</name>
      <address>
        <city>Chandigarh</city>
        <zip>160012</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>March 6, 2023</study_first_submitted>
  <study_first_submitted_qc>March 21, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">April 4, 2023</study_first_posted>
  <last_update_submitted>March 21, 2023</last_update_submitted>
  <last_update_submitted_qc>March 21, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 4, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Postgraduate Institute of Medical Education and Research</investigator_affiliation>
    <investigator_full_name>Ashu Rastogi</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthropathy, Neurogenic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

